A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011–2020

Michael W. Dunne¹², Steven I. Aronin², Kalvin C. Yu³, Janet A. Watts³ and Vikas Gupta³*

Abstract

Background: Urinary tract infections (UTIs), which are usually caused by bacteria in the Enterobacterales family, are a common reason for outpatient visits. Appropriate empiric therapy for UTIs requires an understanding of antibiotic resistance in the community. In this nationwide study, we examined trends in antibiotic resistance in urinary Enterobacterales isolates from ambulatory patients in the United States (US).

Methods: We analyzed the antimicrobial susceptibility profiles (extended-spectrum beta-lactam [ESBL]-producing phenotype and not susceptible [NS] to beta-lactams, trimethoprim/sulfamethoxazole [TMP/SMX], fluoroquinolones [FQ], or nitrofurantoin [NFT]) of 30-day non-duplicate Enterobacterales isolates from urine cultures tested at ambulatory centers in the BD Insights Research Database (2011–2020). The outcome of interest was the percentage of resistant isolates by pathogen and year. Multi-variable generalized estimating equation models were used to assess trends in resistance over time and by additional covariates.

Results: A total of 338 US facilities provided data for > 2.2 million urinary Enterobacterales isolates during the 10-year study. Almost three-quarters (72.8%) of Enterobacterales isolates were Escherichia coli. Overall unadjusted resistance rates in Enterobacterales isolates were 57.5%, 23.1%, 20.6%, and 20.2% for beta-lactams, TMP/SMX, FQ, and NFT, respectively, and 6.9% had an ESBL-producing phenotype. Resistance to two or more antibiotic classes occurred in 16.4% of isolates and 5.5% were resistant to three or more classes. Among isolates with an ESBL-producing phenotype, 70.1%, 59.9%, and 33.5% were NS to FQ, TMP/SMX, and NFT, respectively. In multivariable models, ESBL-producing and NFT NS Enterobacterales isolates increased significantly (both P < 0.001), while other categories of resistance decreased. High rates (≥ 50%) of beta-lactam and NFT resistance were observed in Klebsiella isolates and in non-E. coli, non-Klebsiella Enterobacterales isolates.

Conclusions: Antimicrobial resistance was common in urinary Enterobacterales isolates. Isolates with an ESBL-producing phenotype increased by about 30% between 2011 and 2020, and significant increases were also observed in NFT NS Enterobacterales isolates. Resistance rates for all four antibiotic classes were higher than thresholds recommended for use as empiric therapy. Non-E. coli Enterobacterales isolates showed high levels of resistance to

*Correspondence: vikas.gupta@bd.com
¹ Becton, Dickinson and Company, 1 Becton Drive, Franklin Lakes, NJ 07417, USA
Full list of author information is available at the end of the article
Background
Urinary tract infections (UTIs) are a common reason for outpatient and emergency department visits. Between 2006 and 2010, UTI visits accounted for an estimated 40.9 million ambulatory visits in the United States [1], and the rate of outpatient UTIs is increasing [2]. Most community-onset uncomplicated UTIs (uUTIs) are caused by members of the Enterobacterales family, including Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis [3]. Increasing rates of antimicrobial resistance in ambulatory UTI Enterobacterales isolates have obscured disease management [4–7]. Antibiotic-resistant UTIs are associated with high rates of discordance between antibiotic selection and isolate susceptibility and with treatment failure [8–11]. Furthermore, antimicrobial resistance has been proposed as a key driver for the dramatic increase in US hospitalizations for UTIs due to the need for treatment with intravenous antimicrobials [12].

Infectious Disease Society of America (IDSA) guidelines from 2010 recommend several therapeutic options for empiric treatment of uUTIs (cystitis), including nitrofurantoin (NFT), trimethoprim/sulfamethoxazole (TMP/SMX), and fosfomycin; fluoroquinolones (FQ) and beta-lactams are listed as additional options if the recommended antimicrobials cannot be used or are not effective [3]. The IDSA guidelines also specify that TMP/SMX should be avoided in treatment of acute cystitis if local resistance rates are > 20%, and FQ should be avoided in treatment of acute pyelonephritis if local resistance rates are > 10%. Of note, the US Food and Drug Administration (FDA) subsequently issued a drug safety announcement indicating that FQ should not be used for uUTIs because of the risk of serious side effects [13]. As a result, there are now limited preferred agents for uUTIs, and antimicrobial resistance further diminishes their utility.

Appropriate empiric management of outpatient UTIs requires an understanding of current antimicrobial susceptibility profiles for key pathogens circulating in the community. The objective of the study was to examine trends in antibiotic resistance in Enterobacteriales isolated from urine cultures tested in the ambulatory setting.

Methods
Study design
These analyses are derived from a retrospective cohort study of antimicrobial susceptibility of specified non-duplicate (first isolate of a species in 30 days) Enterobacteriales urine isolates from adult male and female patients (age ≥ 18 years) collected in the ambulatory setting (e.g., non-inpatient with no subsequent admission in the next day) during the time period spanning the first quarter (Q1) of 2011 to the last quarter (Q4) of 2020. Our analyses were based solely on culture results; patients were not required to have symptoms or a UTI diagnosis to be included in the study. Reporting institutions consisted of ambulatory sites affiliated with US hospitals in the BD Insights Research Database (Becton, Dickinson and Company, Franklin Lakes, NJ), which provides geographical representation across the US and includes small and large hospitals in urban and rural areas [14–16].

Pathogen identification and susceptibility results were based on facility reports from healthcare facilities in the BD Insights Research Database using commercial panels and local laboratory breakpoints. Central laboratory testing was not performed. We evaluated five categories of antimicrobial resistance in Enterobacteriales urine isolates using the following definitions:

1. **Organisms with an extended-spectrum beta-lactamase (ESBL)-producing phenotype:** E. coli, K. pneumoniae, Klebsiella oxytoca, and P. mirabilis urine isolates confirmed as ESBL-positive per commercial panels or based on a result of intermediate (I) or resistant (R) to antimicrobial susceptibility tests with extended-spectrum cephalosporins (ceftriaxone, cefotaxime, ceftazidime, or cefepime; ESC4).
2. **Beta-lactam not susceptible (NS) organisms:** Isolates with an ESBL-positive per commercial panels or based on a result of intermediate (I) or resistant (R) to antimicrobial susceptibility tests with extended-spectrum cephalosporins (ceftriaxone, cefotaxime, ceftazidime, or cefepime; ESC4).
3. **TMP/SMX NS organisms:** Enterobacteriales urine isolates testing I or R to TMP/SMX.
| Organism          | Antimicrobial resistance | ESBL phenotype | Beta-lactam | Trimethoprim/sulfamethoxazole | Fluoroquinolones | Nitrofurantoin |
|-------------------|--------------------------|----------------|-------------|-------------------------------|------------------|----------------|
|                   |                          | Tested         | NS          | % NS                          | Tested           | NS             | Tested         | NS          | % NS          | Tested         | NS          | % NS          |
| All               |                          | 2,095,447      | 145,448     | 6.9                           | 2,228,515        | 513,945        | 23.1           | 2,228,515    | 459,339       | 20.6           | 2,228,515    | 450,818       | 20.2          |
| E. coli           |                          | 1,623,448      | 116,843     | 7.2                           | 1,623,448        | 817,083        | 50.3           | 1,623,448    | 376,459       | 23.2           | 1,623,448    | 64,194        | 4.0           |
| K. pneumoniae     |                          | 301,628        | 17,359      | 5.8                           | 301,628          | 33,231         | 11.0           | 301,628      | 18,003        | 6.0            | 301,628      | 174,453       | 57.8          |
| P. mirabilis      |                          | 139,204        | 8991        | 6.5                           | 139,204          | 36,105         | 25.9           | 139,204      | 43,767        | 31.4           | 139,204      | 124,276       | 89.3          |
| E. cloacae        |                          | 39,007         | 35,090      | 90.0                          | 39,007           | 5442           | 14.0           | 39,007       | 3110          | 8.0            | 39,007       | 25,143        | 64.5          |
| K. oxytoxica      |                          | 31,167         | 2255        | 7.2                           | 31,167           | 2939           | 9.4            | 31,167       | 1715          | 5.5            | 31,167       | 5010          | 16.1          |
| K. aerogenes      |                          | 30,234         | 26,770      | 88.5                          | 30,234           | 836            | 2.8            | 30,234       | 889           | 2.9            | 30,234       | 23,851        | 78.9          |
| C. freundii       |                          | 28,300         | 25,808      | 91.2                          | 28,300           | 4473           | 15.8           | 28,300       | 2668          | 9.4            | 28,300       | 2012          | 7.1           |
| M. morganii       |                          | 16,162         | 15,585      | 96.4                          | 16,162           | 5609           | 34.7           | 16,162       | 5799          | 35.9           | 16,162       | 14,256        | 88.5          |
| P. stuartii       |                          | 7916           | 7675        | 97.0                          | 7916             | 2272           | 28.7           | 7916         | 5957          | 75.3           | 7916         | 6984          | 88.2          |
| S. marcescens     |                          | 11,449         | 10,426      | 91.1                          | 11,449           | 337            | 2.9            | 11,449       | 972           | 8.5            | 11,449       | 10,599        | 92.6          |

ESBL extended-spectrum beta-lactamase-producing phenotype, NS not susceptible
4. FQ NS organisms: Enterobacterales urine isolates testing I or R to ciprofloxacin, levofloxacin, or moxifloxacin.
5. NFT NS organisms: Enterobacterales urine isolates testing I or R to NFT.

Outcomes
For each of the five categories of resistance defined above, we evaluated the percent of resistance (number of resistant isolates per total isolates tested) overall, by specific pathogen, by year, and by treatment facility characteristics.

Statistical analysis
Descriptive statistics of percent of resistant isolates over time were presented by cross-tabulation. The covariates considered in the multi-variable modeling analysis included hospital bed size (grouped to three categories: <100, 100–300, and >300), urban/rural status, teaching status, and geographic region (based on US census regions). Generalized estimating equation GEE models with autoregressive variance–covariance structure and with hospitals as random effect were used to assess the effects of season as determined by quarterly data and other covariates on resistance. All statistical analyses were conducted using R V 4.0.3 (R Core Team 2020) and the R geepack package. P values < 0.05 were considered statistically significant.

Results
A total of 338 facilities provided data during the 10-year study period (Additional file 1: Table S1). About two-thirds of the facilities (65.7%) were classified as urban, 67.8% were affiliated with non-teaching hospitals, and 24.9% were affiliated with hospitals with >300 beds. Geographically, the largest concentrations of facilities were in the West South Central (18.9%) and Middle Atlantic (16.9%) region.

Resistance by drug class
Over the 10-year period, more than 2 million Enterobacterales urinary isolates were evaluated for an ESBL-producing phenotype and more than 2.2 million isolates were evaluated for the other resistance profiles. Of the 2,228,515 urinary isolates evaluated for beta-lactam, TMP/SMX, FQ, and NFT resistance, the most common bacteria were E. coli (1,623,448 [72.8%]), K. pneumoniae (301,628 [13.5%]) and P. mirabilis (139,204 [6.2%]) (Table 1). Descriptive statistics showed that the highest rate of antibiotic resistance in Enterobacterales urinary isolates over the 10-year period was to beta-lactams (57.5%), followed by TMP/SMX (23.1%), FQ (20.6%), NFT (20.2%), and ESBL-producing phenotype (6.9%) (Table 1). Quarterly mean rates of resistance were similar (Additional file 1: Table S2).

Observed rates of resistance varied by characteristics of the clinical setting associated with the ambulatory facility at which the test was performed (urban/rural location, bed size, and teaching status) and by census region (Additional file 1: Table S2). Significant associations between larger hospitals (based on bed size) and higher resistance rates were observed for several pathogen/resistance profiles, including ESBL-producing E. coli and Klebsiella isolates, beta-lactam-resistant Enterobacterales isolates, TMP/SMX- and FQ-resistant Klebsiella, and NTF-resistant non-E. coli/Klebsiella Enterobacterales isolates. The highest rates of Enterobacterales isolates with an ESBL-producing phenotype were observed in the Pacific and West South Central region.

Resistance to two or more antibiotic classes occurred in 16.4% of isolates and 5.5% were resistant to three or more classes. Of 145,448 isolates with an ESBL-producing phenotype, 70.1%, 59.9%, and 33.5% were NS to FQ, TMP/SMX, and NFT, respectively (Table 2). A total of 30,698 isolates (21.2% of ESBL-producing phenotype isolates and 1.4% of all isolates) were NS to TMP/SMX, FQ, and NFT.

Trends in antibiotic-resistant urinary Enterobacterales over time
In multivariable adjusted analyses, the percent of isolates with an ESBL-producing phenotype increased by 30% between 2011 and 2020 from 6.5% (95% confidence interval [CI] 6.3–6.8) in 2011 to 9.4% (95% CI 9.1–9.6%) in 2020 (P < 0.001) (Table 3). NFT resistance rates showed a curvilinear trend, but the overall increase over time was confirmed in adjusted GEE models. Resistance to NFT increased from 21.6% (95% CI 21.1–22.4) in 2011 to 22.3% (95% CI 21.7–23.1) in 2020 (P < 0.001). In contrast, the percent of resistant isolates in the other three antimicrobial resistance groups decreased modestly, but significantly, during this time period (all P < 0.001). Resistance to two or more drug classes (from 19.7% [95% CI 19.1–20.0] in 2011 to 18.0% [95% CI, 17.4–18.4] in 2020) and to three or more drug classes (from 6.7% [95% CI 6.5–6.9] in 2011 to 6.5% [95% CI 6.3–6.7] in 2020) also decreased significantly (both P < 0.001). We observed significant changes in seasonal patterns that varied by resistance group (Table 3). The highest rates for isolates resistant to beta-lactams, FQ, and TMP-SMX occurred during Q1, whereas the highest ESBL-producing phenotype and NFT NS rates were observed in Q4. Resistance estimates based on characteristics of the clinical facility...
associated with the site at which the urinary culture was tested are presented in Additional file 1: Table S3.

**Trends in antibiotic-resistant urinary Enterobacterales by pathogen**

Multivariable adjusted subgroup analyses by pathogen found that resistance trends, seasonal patterns, and geographic variations for *E. coli* were generally similar to those observed for all resistant urinary Enterobacterales isolates (Table 4). Specifically, an increasing trend over the years was observed for ESBL-producing phenotype (P<0.001) and decreasing trends were observed for beta-lactams, TMP/SMX, and FQ resistance (all P<0.03). In contrast to the increased resistance to NFT observed in all Enterobacterales urinary isolates, *E. coli* isolates showed reduced resistance to NFT over time (P<0.001). In addition, although the proportion of *E. coli* isolates resistant to two or more drug classes showed a slight but significant decrease during this time period (from 17.8% [95% CI 17.3–18.1] in 2011 to 17.6% [95% CI 17.2–17.9] in 2020; P=0.027), a significant increase was observed in the proportion of *E. coli* isolates resistant to three or more drug classes (from 4.3% [95% CI 4.2–4.4] in 2011 to 5.6% [95% CI 5.5–5.7] in 2020; P<0.001).

*Klebsiella* isolates (K. pneumoniae, *K. oxytoca*, and *K. aerogenes*) accounted for 16.3% (363,029/2,228,515) of isolates analyzed for beta-lactam, FQ, NFT, and TMP/SMX resistance and 15.9% (332,795/2,095,447) of isolates in ESBL-producing phenotype analyses, which did not include *K. aerogenes* (Table 1). With the exception of beta-lactams, the percent of *Klebsiella* isolates with resistant phenotypes increased over time for all drug classes (all P<0.001) (Table 5). Increases were also observed in the proportion of isolates resistant to three or more drugs, but not for two or more drugs (data not shown). Significant changes in seasonal patterns were found for beta-lactam- and NFT-NS *Klebsiella* isolates (P=0.04 and <0.001, respectively), but not for ESBL-producing phenotype or TMP/SMX- or FQ-NS isolates. Compared with 2020 resistance rates observed in the analysis of all Enterobacterales isolates (Table 3), *Klebsiella* showed substantially higher rates of resistance to beta-lactams (81.1% [95% CI 80.5–81.7] vs 56.1% [95% CI 55.6–56.4]) and NFT (59.2% [95% CI 57.9–60.6] vs 22.3% [95% CI 21.7–23.1]), but lower rates of resistance to FQ (6.8% [95% CI 5.6–7.1] vs 21.9% [95% CI 21.3–22.5]) and TMP/SMX (11.3% [95% CI 11.1–11.5] vs 23.9% [95% CI 23.2–24.4]) and lower rates of ESBL-producing phenotype (7.2% [95% CI 7.0–7.3] vs 9.4% [95% CI 9.1–9.6]).

“Other” (non-*E. coli*, non-*Klebsiella*) Enterobacterales isolates included *C. freundii*, *E. cloacae*, *M. morganii*, *P. mirabilis*, *P. stuartii*, and *S. marcescens* and accounted for 242,038 (10.9%) of all isolates (Table 1, Additional file 1: Table S4). This subgroup of Enterobacterales isolates had different resistance profiles from Enterobacterales isolates as a whole, most notably in NFT NS isolates (75.6% [95% CI 74.4–76.9] in 2020 for “other” isolates compared with 22.3% [95% CI 21.7–23.1] for all Enterobacterales isolates). The proportion of these isolates resistant to two or more drug classes or to three or more drugs classes decreased significantly during this time period (data not shown).

**Discussion**

In this study of ambulatory US patients, over half of Enterobacterales-positive urinary cultures were due to organisms resistant to at least one antibiotic class. Although it was encouraging to note a downward trend in resistance to beta-lactams, TMP/SMX, and FQ among Enterobacterales isolates over time, rates were only lower by 2–5% over the 10-year period and suggest that resistance to these classes is firmly established in the community. More disconcerting is the increase observed in NFT NS isolates and particularly in ESBL-producing
### Table 3  All Enterobacterales isolates: adjusted estimates for resistance over time and by geographic region

| Characteristics | ESBL       | Beta-lactam | Trimethoprim/ sulfamethoxazole | Fluoroquinolone | Nitrofurantoin |
|-----------------|------------|-------------|---------------------------------|-----------------|----------------|
|                 | Est (95% CI) | P           | Est (95% CI) | P           | Est (95% CI) | P           | Est (95% CI) | P           | Est (95% CI) | P           |
| Year            |            |             |                   |               |               |             |               |               |             |               |
| 2011            | 6.5 (6.3–6.8) | <0.001      | 60.5 (60.2–60.9) | 25.7 (25.1–26.2) | 25.6 (25.0–26.2) | 21.6 (21.1–22.4) |
| 2012            | 6.8 (6.5–7.0) | <0.001      | 59.9 (59.5–60.3) | 26.5 (25.9–27.0) | 25.0 (24.4–25.5) | 23.1 (22.5–23.9) |
| 2013            | 6.9 (6.7–7.1) | <0.001      | 59.0 (58.6–59.4) | 26.2 (25.6–26.8) | 24.2 (23.7–24.8) | 22.4 (21.9–23.2) |
| 2014            | 7.3 (7.1–7.6) | <0.001      | 58.4 (58.0–58.8) | 25.7 (25.1–26.2) | 23.8 (23.3–24.4) | 22.5 (21.9–23.3) |
| 2015            | 7.5 (7.3–7.8) | <0.001      | 57.7 (57.3–58.1) | 25.6 (25.0–26.2) | 23.2 (22.7–23.8) | 20.9 (20.4–21.8) |
| 2016            | 7.8 (7.5–8.0) | <0.001      | 57.2 (56.7–57.5) | 24.8 (24.2–25.4) | 22.7 (22.1–23.3) | 18.9 (18.4–19.8) |
| 2017            | 8.2 (7.9–8.5) | <0.001      | 56.9 (56.5–57.4) | 24.6 (23.9–25.2) | 22.3 (21.7–23.0) | 19.0 (18.4–19.9) |
| 2018            | 8.6 (8.3–8.8) | <0.001      | 56.6 (56.2–57.0) | 24.5 (23.9–25.1) | 22.1 (21.5–22.8) | 20.2 (19.7–21.1) |
| 2019            | 8.9 (8.7–9.2) | <0.001      | 56.3 (55.8–56.7) | 24.6 (23.9–25.1) | 22.2 (21.5–22.8) | 21.9 (21.4–22.7) |
| 2020            | 9.4 (9.1–9.6) | <0.001      | 56.1 (55.6–56.4) | 23.9 (23.2–24.4) | 21.9 (21.3–22.5) | 22.3 (21.7–23.1) |
| Season (quarter)|            |             |                   |               |               |             |               |               |             |               |
| 1               | 8.2 (6.5–9.9) | 0.015       | 57.8 (56.7–58.9) | 25.4 (24.2–26.2) | 23.5 (22.2–24.7) | 20.8 (18.6–22.8) |
| 2               | 8.1 (6.3–9.9) | 0.009       | 57.5 (56.3–58.5) | 25.3 (24.1–26.2) | 23.1 (21.8–24.3) | 20.7 (18.4–22.7) |
| 3               | 7.9 (62–98)  | <0.001      | 56.9 (55.7–57.9) | 24.3 (23.1–25.2) | 22.3 (21.0–23.6) | 20.9 (18.5–22.9) |
| 4               | 8.3 (66–100) | <0.001      | 57.2 (56.1–58.2) | 24.7 (23.5–25.6) | 22.7 (21.5–23.9) | 21.9 (19.7–23.9) |
| Census regiona  |            |             |                   |               |               |             |               |               |             |               |
| East North Central | 5.7 (3.7–7.6) | 0.003       | 55.9 (54.4–57.3) | 21.6 (19.8–22.9) | 18.7 (16.9–20.5) | 20.2 (17.6–23.0) |
| East South Central | 9.2 (7.2–11.1) |            | 64.2 (62.6–65.7) | 29.1 (27.3–30.4) | 28.2 (26.3–30.0) | 23.1 (20.4–25.7) |
| Middle Atlantic  | 8.1 (6.2–10.1) | <0.001      | 58.6 (57.2–60.1) | 22.9 (21.1–24.1) | 22.4 (20.6–24.2) | 21.2 (18.6–24.1) |
| Mountain         | 4.9 (3.0–6.9) |            | 57.3 (55.9–58.8) | 22.5 (20.6–23.7) | 17.6 (15.8–19.4) | 16.6 (14.0–19.2) |
| New England      | 12.1 (10.9–13.3) | <0.001   | 65.5 (64.5–66.5) | 23.5 (21.9–24.7) | 19.6 (18.4–20.9) | 18.8 (16.6–21.4) |
| Pacific          | 10.6 (8.6–12.5) | <0.001      | 56.1 (54.6–57.6) | 25.8 (24.0–27.1) | 22.6 (20.8–24.4) | 17.9 (15.2–20.5) |
| South Atlantic   | 7.4 (5.4–9.3) | <0.001      | 52.5 (51.0–54.0) | 23.7 (21.9–25.0) | 22.7 (20.9–24.5) | 22.9 (20.3–25.6) |
| West North Central | 8.8 (7.6–10.0) |            | 52.4 (51.4–53.3) | 24.3 (22.8–25.5) | 24.6 (23.4–25.8) | 22.0 (19.9–24.6) |
| West South Central | 8.6 (6.6–10.5) |            | 54.1 (52.7–55.6) | 26.3 (24.4–27.7) | 22.7 (20.9–24.5) | 21.4 (18.7–24.1) |

CI confidence interval, ESBL extended-spectrum beta-lactamase-producing phenotype, Est estimated, NS not susceptible

* States included in the data sample by census regions were: East North Central: Illinois, Indiana, Michigan, Ohio, and Wisconsin; East South Central: Alabama, Kentucky, Mississippi, and Tennessee; Middle Atlantic: New Jersey, New York, and Pennsylvania; Mountain: Arizona, Idaho, Montana, and New Mexico; New England: Connecticut and New Hampshire; Pacific: California, Oregon, and Washington; South Atlantic: Delaware, Georgia, Florida, Maryland, North Carolina, South Carolina, Washington D.C., West Virginia, and Virginia; West North Central: Iowa and Missouri; West South Central: Louisiana, Oklahoma, Texas.
Table 4  

*E. coli* isolates: adjusted estimates for resistance over time and by geographic region  

| Characteristics | ESBL | Beta-lactam | Trimethoprim/ sulfamethoxazole | Fluoroquinolones | Nitrofurantoin |
|-----------------|------|-------------|--------------------------------|-----------------|---------------|
|                 | Est (95% CI) | P | Est (95% CI) | P | Est (95% CI) | P | Est (95% CI) | P | Est (95% CI) | P |
| **Year**        |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 2011            | 6.3 (6.0–6.6) | <0.001 | 54.7 (53.9–55.5) | <0.001 | 277 (272–282) | 0.029 | 26.0 (25.3–26.6) | <0.001 | 4.5 (3.4–5.5) | <0.001 |
| 2012            | 6.6 (6.3–6.9) | <0.001 | 54.1 (53.3–54.9) | <0.001 | 293 (288–298) |       | 270 (264–275) | <0.001 | 6.5 (5.4–7.5) | <0.001 |
| 2013            | 6.8 (6.6–7.1) | <0.001 | 53.4 (52.6–54.1) | <0.001 | 28.9 (284–294) |       | 265 (259–270) | <0.001 | 6.2 (5.1–7.1) | <0.001 |
| 2014            | 7.4 (7.1–7.7) | <0.001 | 52.9 (52.1–53.7) | <0.001 | 28.8 (28.3–29.3) |       | 263 (257–268) | <0.001 | 6.2 (4.9–7.2) | <0.001 |
| 2015            | 7.7 (7.4–8.0) | <0.001 | 52.1 (51.4–52.9) | <0.001 | 28.5 (27.9–29.0) |       | 258 (252–263) | <0.001 | 4.6 (2.9–5.7) | <0.001 |
| 2016            | 8.1 (7.8–8.4) | <0.001 | 51.5 (50.6–52.3) | <0.001 | 27.6 (27.1–28.1) |       | 255 (249–260) | <0.001 | 3.5 (1.9–4.6) | <0.001 |
| 2017            | 8.6 (8.3–8.9) | <0.001 | 51.2 (50.4–52.1) | <0.001 | 27.7 (27.1–28.2) |       | 253 (247–259) | <0.001 | 3.5 (1.9–4.6) | <0.001 |
| 2018            | 9.1 (8.8–9.4) | <0.001 | 50.9 (50.1–51.8) | <0.001 | 28.1 (27.6–28.7) |       | 253 (247–260) | <0.001 | 3.9 (2.3–5.0) | <0.001 |
| 2019            | 9.7 (9.4–10.0) | <0.001 | 50.8 (49.9–51.5) | <0.001 | 28.6 (28.0–29.2) |       | 256 (249–262) | <0.001 | 4.3 (2.7–5.4) | <0.001 |
| 2020            | 9.8 (9.5–10.2) | <0.001 | 50.6 (49.7–51.4) | <0.001 | 27.3 (26.7–27.8) |       | 257 (250–263) | <0.001 | 4.1 (2.4–5.2) | <0.001 |
| **Season (quarter)** | 0.009 | <0.001 | 0.001 | <0.001 | 0.031 | <0.001 | 0.044 | <0.001 | 0.044 | <0.001 |
| 1               | 8.6 (6.3–10.8) | <0.001 | 52.6 (51.6–53.6) | <0.001 | 28.6 (27.3–29.4) |       | 264 (262–266) | <0.001 | 4.6 (3.3–6.4) | <0.001 |
| 2               | 8.4 (6.2–10.8) | <0.001 | 52.0 (51.0–53.0) | <0.001 | 28.5 (27.1–29.3) |       | 262 (260–265) | <0.001 | 4.6 (3.3–6.4) | <0.001 |
| 3               | 8.3 (6.0–10.7) | <0.001 | 51.0 (49.9–52.0) | <0.001 | 27.6 (26.2–28.5) |       | 251 (249–254) | <0.001 | 4.3 (3.0–6.1) | <0.001 |
| 4               | 8.7 (6.5–11.0) | <0.001 | 51.5 (50.5–52.5) | <0.001 | 27.9 (26.5–28.6) |       | 255 (252–257) | <0.001 | 4.4 (3.0–6.2) | <0.001 |
| **Census region** | <0.001 | <0.001 | <0.001 | <0.001 | 0.044 | <0.001 | <0.001 | <0.001 | <0.001 |
| East North Central | 5.7 (3.1–8.2) | <0.001 | 47.4 (45.6–49.2) | <0.001 | 24.5 (22.5–25.6) |       | 20.8 (19.9–21.6) | <0.001 | 3.9 (2.6–5.9) | <0.001 |
| East South Central | 9.8 (7.2–12.3) | <0.001 | 59.1 (57.2–60.9) | 33.1 (31.2–34.3) | 32.2 (31.3–33.0) | <0.001 | 54 (9.7–2) | <0.001 |
| Middle Atlantic | 8.4 (5.8–10.9) | <0.001 | 51.1 (49.4–52.9) | <0.001 | 25.4 (23.5–26.5) | <0.001 | 45 (8.1–6.6) | <0.001 |
| Mountain | 5.1 (2.6–7.6) | <0.001 | 48.4 (46.7–50.2) | <0.001 | 23.7 (21.9–24.9) | <0.001 | 45 (3.4–5.6) | <0.001 |
| New England | 11.8 (10.3–13.4) | <0.001 | 61.5 (60.1–62.8) | <0.001 | 26.4 (25.1–27.7) | <0.001 | 27 (2.1–3.5) | <0.001 |
| Pacific | 10.8 (8.3–13.4) | <0.001 | 49.8 (48.0–51.5) | <0.001 | 27.7 (25.8–28.9) | <0.001 | 42 (2.8–6.2) | <0.001 |
| South Atlantic | 7.6 (5.1–10.2) | <0.001 | 47.4 (45.7–49.2) | <0.001 | 27.7 (25.8–28.8) | <0.001 | 46 (3.3–6.5) | <0.001 |
| West North Central | 11.6 (10.1–13.2) | <0.001 | 46.1 (44.8–47.4) | <0.001 | 26.2 (24.8–27.5) | <0.001 | 28 (2.1–4.8) | <0.001 |
| West South Central | 9.2 (6.6–11.7) | <0.001 | 53.2 (51.4–55.0) | <0.001 | 30.6 (28.7–31.8) | <0.001 | 44 (5.0–6.4) | <0.001 |

*CI* confidence interval, ESBL extended-spectrum beta-lactamase-producing phenotype, *Est* estimated, NS not susceptible
| Characteristics          | ESBL                      | Beta-lactam                  | Trimethoprim–sulfamethoxazole | Fluoroquinolones | Nitrofurantoin |
|--------------------------|---------------------------|-----------------------------|--------------------------------|------------------|---------------|
|                         | Est (95% CI) P            | Est (95% CI) P              | Est (95% CI) P                 | Est (95% CI) P   | Est (95% CI) P |
| **Year**                 |                           |                             |                                |                  |               |
| 2011                     | 63 (6.2–6.4) < 0.001      | 928 (923–93.4) < 0.001      | 11.0 (10.9–11.2) < 0.001       | 67 (4.6–80) 58.5 (57.1–59.7) |
| 2012                     | 64 (6.2–6.5) < 0.001      | 914 (909–91.9) < 0.001      | 10.4 (10.2–10.6)               | 69 (4.9–82) 60.0 (58.6–61.2) |
| 2013                     | 64 (6.3–6.5) < 0.001      | 895 (889–900) 9.9 (9.6–10.1) | 9.3 (9.0–9.5) 56 (4.4–69)     | 69 (4.9–82) 60.8 (59.4–62.0) |
| 2014                     | 66 (6.4–6.7) < 0.001      | 877 (871–88.2) 9.3 (9.0–9.5) | 10.5 (10.2–10.7) 6.2 (5.0–7.5) | 59.8 (58.4–61.0) |
| 2015                     | 66 (6.5–6.7) < 0.001      | 868 (862–87.3) 10.5 (10.2–10.7) | 10.4 (10.2–10.6) 5.9 (4.7–7.1) | 57.2 (55.8–58.4) |
| 2016                     | 66 (6.5–6.7) < 0.001      | 858 (853–86.4) 10.5 (10.2–10.7) | 10.6 (10.3–10.8) 6.0 (4.8–7.2) | 52.5 (51.2–53.9) |
| 2017                     | 6.7 (6.6–6.9) < 0.001     | 849 (843–85.5) 10.3 (10.0–10.5) | 10.5 (10.3–10.8) 6.0 (4.8–7.2) | 53.4 (52.0–54.8) |
| 2018                     | 6.8 (6.7–7.0) < 0.001     | 840 (83.5–84.6) 10.6 (10.3–10.8) | 10.5 (10.3–10.8) 6.0 (4.8–7.2) | 54.7 (53.3–56.1) |
| 2019                     | 6.9 (6.8–7.1) < 0.001     | 828 (822–83.4) 11.4 (11.1–11.6) | 11.3 (11.1–11.5) 6.8 (5.6–7.1) | 55.2 (54.0–56.6) |
| 2020                     | 7.2 (7.0–7.3) < 0.001     | 81.1 (80.5–81.7) 11.3 (11.1–11.5) | 11.3 (11.1–11.5) 6.8 (5.6–7.1) | 59.2 (57.9–60.6) |
| **Season (quarter)**     |                           |                             |                                |                  |               |
| 1                        | 6.9 (6.1–7.8) 0.036       | 86.1 (81.9–90.3) 10.8 (9.2–12.1) | 10.8 (9.2–12.1) 6.5 (5.7–7.4) | 55.8 (51.3–60.1) |
| 2                        | 6.8 (6.0–7.7) 0.036       | 85.6 (81.1–85.8) 10.5 (9.0–11.9) | 10.5 (9.0–11.9) 6.3 (5.4–7.1) | 55.4 (50.6–59.7) |
| 3                        | 6.7 (5.9–7.5) 0.036       | 85.1 (80.9–89.3) 10.4 (8.8–11.8) | 10.4 (8.8–11.8) 6.1 (5.2–6.9) | 57.2 (52.3–61.5) |
| 4                        | 6.6 (5.8–7.4) 0.036       | 84.8 (80.3–890) 10.7 (9.1–12.2) | 10.7 (9.1–12.2) 6.2 (5.3–7.1) | 57.7 (53.0–62.0) |
| **Census region**        |                           |                             |                                |                  |               |
| East North Central       | 5.1 (4.1–6.0) 0.003       | 93.5 (88.8–98.2) 9.2 (7.3–10.6) | 9.2 (7.3–10.6) 6.2 (5.2–7.2) | 54.2 (48.5–59.6) |
| East South Central       | 7.2 (6.2–8.3) 0.003       | 91.4 (86.3–96.2) 11.6 (10.0–13.0) | 11.6 (10.0–13.0) 6.8 (5.7–7.8) | 58.0 (52.3–62.7) |
| Middle Atlantic          | 7.1 (6.1–8.1) 0.003       | 93.3 (88.6–98.0) 10.7 (9.0–12.2) | 10.7 (9.0–12.2) 5.4 (4.3–6.4) | 56.6 (50.9–61.9) |
| Mountain                 | 4.7 (3.5–5.7) 0.003       | 86.4 (81.7–91.2) 8.1 (6.6–9.5) | 8.1 (6.6–9.5) 3.6 (2.9–4.6) | 52.6 (46.9–57.8) |
| New England              | 3.6 (3.0–4.2) 0.003       | 85.2 (82.3–88.1) 7.9 (7.1–8.8) | 7.9 (7.1–8.8) 5.0 (4.3–6.4) | 56.1 (520–61.3) |
| Pacific                  | 8.6 (7.6–9.6) 0.003       | 87.6 (82.9–92.3) 10.7 (8.8–12.1) | 10.7 (8.8–12.1) 7.0 (5.9–8.1) | 56.4 (507–61.8) |
| South Atlantic           | 7.0 (6.0–7.9) 0.003       | 74.7 (70.0–79.5) 10.7 (8.9–12.0) | 10.7 (8.9–12.0) 7.0 (5.9–8.0) | 61.6 (560–67.1) |
| West North Central       | 3.6 (2.9–4.3) 0.003       | 94.9 (91.9–97.7) 7.8 (6.3–9.0) | 7.8 (6.3–9.0) 2.0 (1.1–3.0) | 48.2 (439–53.4) |
| West South Central       | 7.2 (6.2–8.1) 0.003       | 69.4 (64.6–74.1) 11.7 (9.7–13.3) | 11.7 (9.7–13.3) 6.4 (5.3–7.5) | 55.6 (500–61.1) |

CI confidence interval, ESBL extended-spectrum beta-lactamase-producing phenotype, Est estimated, NS not susceptible

* K. pneumoniae, K. oxytoca, and K. aerogenes
Outpatient UTIs caused by Enterobacterales isolates with an ESBL-producing phenotype were associated with a sevenfold increase in clinical failure compared with non-ESBL-producing isolates [9], and inpatients with UTIs due to ESBL-producing isolates have a longer hospital length of stay, higher mortality, and higher rates of re-admission [22, 23]. Due to the morbidity and mortality associated with UTIs due to ESBL-producing organisms, prompt, effective treatment is essential to improving patient outcomes. However, discordant empiric therapy is common in both outpatients and inpatients with UTIs caused by isolates with an ESBL-producing phenotype [8, 9, 23]. As shown in our analyses, Enterobacterales isolates with an ESBL-producing phenotype are often highly resistant to oral agents commonly used to treat UTIs. Although the isolates generally retain susceptibility to carbapenems [24], these agents are currently only available in intravenous formulations and hospitalization is often required for their use. Additional oral options, including oral penemems, would provide valuable alternatives to currently available antibiotics used to treat outpatient UTIs.

Although our study did not explore the association between antibiotic use and antibiotic-resistant UTIs, a large body of evidence suggests that community antibiotic use has a strong influence on antibiotic resistance rates [25, 26]. It is therefore possible that decreases in beta-lactams, FQ, and TMP-SMX over time reflect more judicious use of these drugs in the ambulatory setting.

Our study encompasses data from 2020, a time during which the coronavirus disease-2019 (COVID-19) pandemic altered outpatient management [27]. Many healthcare systems view telemedicine as an answer to resource optimization, particularly during surge capacity times such as cold/flu season and more recently the COVID-19 pandemic. However, recent data have shown that while virtual visits may decrease operational costs, the prescribing of antimicrobials often increases with telemedicine [28]. The acquisition of urine cultures also appears to be less frequent for virtual visits [2]. It is therefore possible that the virtual medicine trend augmented by COVID-19 restrictions may impact uUTI management, including potential increases in use of inappropriate antimicrobials and reductions in performing urine cultures. Although we did not observe increased resistance in 2020 urinary Enterobacterales isolates, we did document a reduction in the number of ambulatory cultures analyzed in 2020 compared with 2018–2019, despite the fact that the number of study sites increased. Future analyses will be required to address the underlying reasons for this observation as well as potential effects on patient outcomes.

Seasonal variations in Enterobacterales antimicrobial resistance were identified. Higher rates of resistance lag approximately 1 month behind increased antibiotic usage [29], and it is therefore likely that this seasonality relates to the increased use of oral antibiotics during the influenza season, as has been suggested in other studies [30–32]; this observation warrants further evaluation.

Although we conducted explorative analyses on the association between hospital characteristics of associated testing facilities and antimicrobial resistance, it should be
emphasized that the patients in this study were not hospitalized. Accordingly, the data on geographic variations have the most relevance to the population being examined. In addition to geographic variations, significantly higher resistance rates were observed for testing facilities associated with larger hospitals (>300 beds) for some pathogens/resistance profiles, including ESBL-producing phenotypes for *E. coli* and *Klebsiella* isolates. This observation may relate to a higher likelihood of antimicrobial resistance in more urban areas, but more study will be needed to confirm this connection. Associations with other hospital characteristics were inconsistent and so their potential clinical significance is unclear.

Conservation of effective antimicrobials is an increasingly supported tenet of antimicrobial stewardship, which has recently gained traction in the US with inclusion as an inpatient Centers for Medicare & Medicaid Services Condition of Participation metric and new outpatient standards from The Joint Commission [33]. Through stewardship programs, clinicians are now expected to weigh the risk/benefit ratio of empiric therapy on an individual level while taking into account the aggregate effect on population resistance. In some cases, they are assisted in that decision by the use of electronic medical record-based clinical decision tools designed to aid clinician prescribing for common clinical syndromes such as uUTI and respiratory infections [34, 35]. Nevertheless, the balance between appropriate guideline-endorsed empiric therapy for individual patients and potential aggregate public health issues related to bulk prescribing remains a complicated issue. More complete information on outpatient resistance trends may help the clinician when choosing an empiric uUTI agent. This, coupled with efforts to improve both the development and availability of better diagnostic tests, may in turn enable clinicians to treat based on the individual while taking into account the larger public health consequences of antimicrobial resistance.

Limitations of our study include the identification of non-duplicate culture-positive isolates rather than confirmed clinical infections. Although classification of urinary pathogens versus commensal bacteria is an ongoing area of research [36], the bacteria evaluated in this study are all known to have pathogenic potential and are typically considered pathogens when found in urine. Similarly, our data did not capture whether the affected patient had cystitis or pyelonephritis. The study was not designed to evaluate clinical outcomes associated with positive urinary cultures. Antimicrobial susceptibility results relied on local microbiology practices at each facility and were not standardized across facilities. Enterobacterales testing practices and antibiotic breakpoints are known to vary among different institutions, including susceptibility criteria for ESBL [37], FQ [38], and beta-lactams [39]. Finally, ordering a urine culture is not a common practice for uUTI and in particular in patients who do not have recurring UTIs; the data therefore may more heavily represent a certain subset of the UTI population. Nevertheless, the resistance trends reported here highlight the need for augmented surveillance of local susceptibility patterns to better inform empiric therapy options.

**Conclusions**

Our data provide contemporary insights into antimicrobial resistance trends in the US and document high rates of antimicrobial resistance and increasing ESBL positivity rates in Enterobacterales isolates in urinary cultures from ambulatory patients. These data on antimicrobial resistance may be of value when considering empiric therapy options for patients with UTIs and will serve as valuable benchmarks for antimicrobial stewardship efforts in the outpatient setting.

**Abbreviations**

COVID-19: Coronavirus disease-2019; ESBL: Extended-spectrum beta-lactamase; ESC: Extended-spectrum cephalosporins; FDA: Food and Drug Administration; FQ: Fluoroquinolones; I: Intermediate; IDSA: Infectious Diseases Society of America; NS: Not susceptible; NFT: Nitrofurantoin; Q: Quarter; R: Resistant; TMP/SMZ: Trimethoprim/sulfamethoxazole; UTI: Urinary tract infection; uUTI: Uncomplicated urinary tract infection.

**Supplementary Information**

The online version contains supplementary material available at [https://doi.org/10.1186/s12879-022-07167-y](https://doi.org/10.1186/s12879-022-07167-y).

**Additional file 1:** Table S1. Distribution of study sites. Table S2. Summary statistics (unadjusted) of resistance in ambulatory-onset urinary Enterobacterales isolates over time and by hospital characteristics of the facility associated with the outpatient setting at which the urine culture was collected. % NS data presented as quarterly mean (SD). Table S3. Adjusted estimates for percent of resistance by hospital characteristics and by pathogen. Table S4. Other Enterobacterales organisms excluding *E. coli* and *Klebsiella* spp: adjusted estimates for resistance over time and by geographic region.

**Acknowledgements**

We thank Sharon L. Cross, Ph.D., Fusion MD Medical Science Network, Inc., Montreal, Canada, for providing manuscript support with funding from Becton, Dickinson & Company.

**Authors’ contributions**

MWD, SJA, KCY, JW, and VG were involved in study design and in data analysis and interpretation. KCY and VG drafted the manuscript. JW provided analytic and statistical support. All authors read and approved the final manuscript.

**Funding**

This work was supported by a grant from Iterum Therapeutics, Old Saybrook, CT, US to Becton, Dickinson, and Company, Franklin Lakes, NJ, US. Medical writing was supported by Becton, Dickinson & Company.
Availability of data and materials
The datasets used and/or analyzed during the current study are included in the tables in the main manuscript and additional information.

Declarations

Ethics approval and consent to participate
This study was performed in accordance with all relevant guidelines and regulatory requirements, including the Declaration of Helsinki. Ethical approval for this study was received from the New England Institutional Review Board (Wellesley, Massachusetts; No. 120180023). Outcome studies using this retrospective, deidentified dataset were approved and informed consent was waived by the New England Institutional Review Board (Wellesley, Massachusetts; No. 120180023).

Consent for publication
Not applicable.

Competing interests
MWD and SIA are employees of and own stock in Iterum Therapeutics, KCY, and VG also own stock in Iterum Therapeutics. KCY, MWD and SIA are employees of and own stock in Iterum Therapeutics. KCY, and VG also own stock in Iterum Therapeutics.

Author details
1 Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA. 2 Iterum Therapeutics to conduct the study. KCY and VG also own stock in Iterum Therapeutics. MWD and SIA are employees of and own stock in Iterum Therapeutics. KCY, MWD and SIA are employees of and own stock in Iterum Therapeutics. KCY, and VG also own stock in Iterum Therapeutics.

Received: 8 December 2021 Accepted: 14 February 2022
Published online: 28 February 2022

References
1. May L, Mullins P, Pines J. Demographic and treatment patterns for infections in ambulatory settings in the United States, 2006–2010. Acad Emerg Med. 2014;21:17–24.
2. Bruxvoort KJ, Bider-Canfield Z, Case JA, Qian L, Pressman A, Liang AS, et al. Outpatient urinary tract infections in an era of virtual healthcare: trends from 2008 to 2017. Clin Infect Dis. 2020;70:100–8.
3. Gupta K, Hooton TM, Naicker KG, Wulf B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–20.
4. Lob SH, Nicolle LE, Hoban DJ, Kuczyńska-KM, Badal RE, Sahn DF. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014. Diagn Microbiol Infect Dis. 2016;85:459–65.
5. Sanchez GV, Babiker A, Master RN, Luu T, Mathur A, Bordon J. Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016;60:2680–3.
6. Karlewsky JA, Lagacé-Wiens PRS, Adam HJ, Baxter MR, Laing NM, Walkty AJ, et al. In-vitro susceptibility of urinary isolates of Escherichia coli to first- and second-line empirically prescribed oral antimicrobial agents: CANDARW surveillance study results for Canadian outpatients from 2007 to 2016. Int J Antimicrob Agents. 2019;54:62–8.
7. Kaye KS, Gupta V, Mulgirejiga A, Joshi AV, Scangarella-Oman NE, et al. Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011–2019: rising ESBL strains and impact on patient management. Clin Infect Dis. 2021;73:1992–9.
8. Frazez BW, Trivedi T, Montgomery M, Petrovic DF, Yamaji R, Riley L. Emergency department urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacterales: many patients have no identifiable risk factor and discordant empiric therapy is common. Ann Emerg Med. 2018;72:449–56.
9. Anesi J, Lautenbach E, Nachamkin I, Garrigan C, Bilker WB, Omorogbe J, et al. Poor clinical outcomes associated with community-onset urinary tract infections due to extended-spectrum cephalosporin-resistant Enterobacteriaceae. Infect Control Hosp Epidemiol. 2018;39:1431–5.
10. van Hecke O, Wang K, Lee JJ, Roberts NW, Butler CC. Implications of antibiotic resistance for patients’ recovery from common infections in the community: a systematic review and meta-analysis. Clin Infect Dis. 2017;65:371–82.
11. Dunne MW, Puttagunta S, Aronin SI, Brockett S, Murray J, Gupta V. Impact of empirical antibiotic therapy on outcomes of outpatient urinary tract infection due to non-susceptible Enterobacteriales. Microbiol Spectr. 2022;10:e0235921. https://doi.org/10.1128/spectrum.02359-21.
12. Simmering JE, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. The increase in hospitalizations for urinary tract infections and the associated costs in the United States, 1998–2011. Open Forum Infect Dis. 2017;4:ofw281.
13. US Food and Drug Administration. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. July 26, 2016. https://www.fda.gov/media/119537/download. Accessed 20 May 2021.
14. McCann E, Srinivasan A, DeRijke CA, DePestel DD, Murray J, Gupta V. Carbapenem-nonsusceptible Gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: a multicenter study. Open Forum Infect Dis. 2018;5:ofy241.
15. Gupta V, Ye G, Olesky M, Lawrence K, Murray J, Yu K. Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013–2017. BMC Infect Dis. 2019;19:742.
16. Gupta V, Yu KC, Schranz J, Gelone SP. A multicenter evaluation of the US prevalence and regional variation in macrolide-resistant S. pneumoniae in ambulatory and hospitalized adult patients in the US. Open Forum Infect Dis. 2021;8:ofab083.
17. Dokter J, Tennyson LE, Nguyen L, Han E, Sirls LT. The clinical rate of antibiotic change following empiric therapy for suspected urinary tract infections. Int Urol Nephrol. 2020;52:431–6.
18. Thaden JT, Fowler VG, Sexton DJ, Anderson DJ. Increasing incidence of extended-spectrum β-lactamase-producing Escherichia coli in community hospitals throughout the southeastern United States. Infect Control Hosp Epidemiol. 2016;37:49–54.
19. McDanel J, Schiefer M, Crabb V, Nelson R, Samore M, Khader K, et al. Incidence of extended-spectrum β-lactamases (ESBL)-producing Escherichia coli and Klebsiella infections in the United States: a systematic literature review. Infect Control Hosp Epidemiol. 2017;38:1209–15.
20. Weinstein EJ, Han JH, Lautenbach E, Nachamkin I, Garrigan C, Bilker WB, et al. A clinical prediction tool for extended-spectrum cefepime-resistant E. coli and Klebsiella infections in US hospitals. Open Forum Infect Dis. 2019;6:ofz164.
21. Lodise TP, Bonine NC, Ye JM, Folse HJ, Gillard P. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections. BMC Infect Dis. 2019;19:718.
22. Talan DA, Takahr S, Krishnadass A, Mower WR, Pallin DJ, Garg M, et al. Emergence of extended-spectrum beta-lactamase urinary tract infections among hospitalized emergency department patients in the United States. Ann Emerg Med. 2021;77:32–43.
23. Mark DG, Hung YY, Salim Z, Tarlton NJ, Torres E, Frazee BW. Third-generation cephalosporin resistance and associated discordant antibiotic treatment in emergency department febrile urinary tract infections. Ann Emerg Med. 2021;78:357–69.
24. Crichton IA, Cotrononeo N, Pucci MJ, Mendes R. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS ONE. 2019;14:302265.
25. Stewardson AJ, Vervoort J, Adriaenssens N, Coenen S, Godycki-Cwirko M, Kowalczyk A, et al. Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among community-acquired urinary tract infections among hospitalized emergency department patients. Clin Microbiol Infect. 2019;25:234–41.
26. Xu S, Glenn S, Sy L, Qian L, Hong V, Ryan DS, et al. Impact of the COVID-19 pandemic on health care utilization in a large integrated health care system: retrospective cohort study. J Med Internet Res. 2021;23:e26558.
28. Grimes CL, Balk EM, Crisp CC, Antosh DD, Murphy M, Halder GE, et al. A guide for urogynecologic patient care utilizing telemedicine during the COVID-19 pandemic: review of existing evidence. Int Urogynecol J. 2020;31:1063–89.
29. Sun L, Klein EY, Laxminarayan R. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin Infect Dis. 2012;55:687–94.
30. Polgreen PM, Yang M, Laxminarayan R, Cavanaugh JE. Respiratory fluoroquinolone use and influenza. Infect Control Hosp Epidemiol. 2011;32:706–9.
31. Martinez EF, Cepeita M, Jovaneska M, Bramer WM, Schoufour J, Gilisic M, et al. Seasonality of antimicrobial resistance rates in respiratory bacteria: a systematic review and meta-analysis. PLoS ONE. 2019;14:e0221133.
32. Gupta V, Yu KC, Kabler H, Watts JA, Amiche A. Antibiotic resistance patterns and association with the influenza season in the United States: a multicenter evaluation reveals surprising associations between influenza season and resistance in Gram-negative pathogens. Open Forum Infect Dis. 2022. Manuscript online ahead of print. https://doi.org/10.1093/ofid/ofac039.
33. Infectious Diseases Society of America. Medicare, Joint Commission update antimicrobial stewardship requirements. February 5, 2020. https://www.idsociety.org/idsa-newsletter/february-5-2020/medicare-joint-commission-update-antimicrobial-stewardship-requirements/. Accessed 1 Sept 2021.
34. Gulliford MC, Prevost AT, Charlton J, Juszczynk D, Soames J, McDermott L, et al. Effectiveness and safety of electronically delivered prescribing feedback and decision support on antibiotic use for respiratory illness in primary care: REDUCE cluster-randomized trial. BMJ. 2019;364:k236.
35. Goss FR, Bookman K, Barron M, Bickley D, Landgren B, Kroeht M, et al. Improved antibiotic prescribing using indication-based clinical decision support in the emergency department. J Am Coll Emerg Physicians. 2020;1:214–21.
36. Morand A, Cornu F, Dufour JC, Tsimaratos M, Lagier JC, Raoult D. Human bacterial repertoire of the urinary tract: a potential paradigm shift. J Clin Microbiol. 2019;57:e00675-18.
37. Shugart A, Walters MS, Weiner LM, Lonsway D, Kallen AJ. Hospital microbiology laboratory practices for Enterobacteriaceae: Centers for Disease Control and Prevention National Healthcare Safety Network (NHSN) annual survey, 2015 and 2016. Infect Control Hosp Epidemiol. 2018;39:1115–7.
38. Stehr MM. Adoption of the updated CLSI fluoroquinolone breakpoints for Gram-negative bacteria in microbiology laboratories. Clin Microbiol Infect. 2022;27:308–10.
39. Humphries RM, Abbott AN, Hindler JA. Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories. J Clin Microbiol. 2019;57:e00203-19.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.